BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of ...
Pfizer's obesity-related pipeline is gaining substantial momentum. On February 3, 2026, the company announced positive Phase 2b results from its VESPER-3 study for PF-08653944, a long-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results